Robert W. Carlson

Publications

• mTOR inhibitors in the treatment of breast cancer. Vinayak S, Carlson RW. Oncology (Williston Park). 2013; 27 (1): 38-44, 46, 48 passim
• Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick JA, Sheth S, Kurian AW, Ford JM, Stockdale FE, Quake SR, Pease RF, Mindrinos MN, Bhanot G, Dairkee SH, Davis RW, Jeffrey SS. PLoS One. 2012; 7 (5): e33788
• Invasive breast cancer. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R. J Natl Compr Canc Netw. 2011; 9 (2): 136-222
• Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM. J Am Coll Cardiol. 2010; 56 (20): 1644-50
• Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. Carlson RW, Theriault R, Schurman CM, Rivera E, Chung CT, Phan SC, Arun B, Dice K, Chiv VY, Green M, Valero V. J Clin Oncol. 2010; 28 (25): 3917-21
• First-line chemotherapy for metastatic breast cancer. Telli ML, Carlson RW. Clin Breast Cancer. 2009: 9 Suppl 2 S66-72
• Impaired interferon signaling is a common immune defect in human cancer. Critchley-Thorne RJ, Simons DL, Yan N, Miyahira AK, Dirbas FM, Johnson DL, Swetter SM, Carlson RW, Fisher GA, Koong A, Holmes S, Lee PP. Proc Natl Acad Sci U S A. 2009; 106 (22): 9010-5
• Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer. Svahn TH, Niland JC, Carlson RW, Hughes ME, Ottesen RA, Theriault RL, Edge SB, Schott AF, Bookman MA, Weeks JC. J Natl Compr Canc Netw. 2009; 7 (2): 115-21
• Rational Surveillance Programs for Early Stage Breast Cancer Patients After Primary Treatment. Mollick JA, Carlson RW. Breast Dis. 2009: 21 47-54
• The decline in breast cancer incidence: real or imaginary? Kurian AW, Clarke CA, Carlson RW. Curr Oncol Rep. 2009; 11 (1): 21-8
• New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, Rouse RV, Bailey L, Philben VJ, Dirbas FM, Dunn JJ, Johnson DL, Wapnir IL, Carlson RW, Stockdale FE, Hansen NM, Jeffrey SS. BMC Cancer. 2008: 8 66
• Selecting high priority quality measures for breast cancer quality improvement. Hassett MJ, Hughes ME, Niland JC, Ottesen R, Edge SB, Bookman MA, Carlson RW, Theriault RL, Weeks JC. Med Care. 2008; 46 (8): 762-70
• Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial. Spiegel D, Butler LD, Giese-Davis J, Koopman C, Miller E, DiMiceli S, Classen CC, Fobair P, Carlson RW, Kraemer HC. Cancer. 2007; 110 (5): 1130-8
• Phyllodes tumors of the breast: natural history, diagnosis, and treatment. Telli ML, Horst KC, Guardino AE, Dirbas FM, Carlson RW. J Natl Compr Canc Netw. 2007; 5 (3): 324-30
• Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. Telli ML, Hunt SA, Carlson RW, Guardino AE. J Clin Oncol. 2007; 25 (23): 3525-33
• A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. Carlson RW, O'Neill AM, Goldstein LJ, Sikic BI, Abramson N, Stewart JA, Davidson NE, Wood WC. Cancer Invest. 2006; 24 (7): 677-81
• Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. Carlson RW, Hudis CA, Pritchard KI. J Natl Compr Canc Netw. 2006; 4 (10): 971-9
• Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes? Chan JK, Manuel MR, Cheung MK, Osann K, Husain A, Teng NN, Rao A, Carlson RW, Whittemore AS. Gynecol Oncol. 2006; 102 (3): 508-12
• HER2 testing in breast cancer: NCCN Task Force report and recommendations. Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM. J Natl Compr Canc Netw. 2006: 4 Suppl 3 S1-22; quiz S23-4
• NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC. J Natl Compr Canc Netw. 2006: 4 Suppl 1 S1-26
• Breast cancer. Carlson RW, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis C, Jahanzeb M, Ljung BM, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. J Natl Compr Canc Netw. 2005; 3 (3): 238-89
• Predictors of local recurrence after breast-conservation therapy. Horst KC, Smitt MC, Goffinet DR, Carlson RW. Clin Breast Cancer. 2005; 5 (6): 425-38
• The history and mechanism of action of fulvestrant. Carlson RW, Clin Breast Cancer. 2005: 6 Suppl 1 S5-8
• Update: NCCN breast cancer Clinical Practice Guidelines. Carlson RW, McCormick B. J Natl Compr Canc Netw. 2005: 3 Suppl 1 S7-11
• Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know? Chung CT, Carlson RW. Clin Breast Cancer. 2004: 5 Suppl 1 S18-23
• High-dose chemotherapy and stem cell transplantation does not improve relapse-free or overall survival in women with high-risk breast cancer. Carlson RW, Wheatley K. Cancer Treat Rev. 2004; 30 (1): 131-7
• Rational surveillance programs for early stage breast cancer patients after primary treatment. Mollick JA, Carlson RW. Breast Dis. 2004: 21 47-54
• Treatment of breast cancer in countries with limited resources. Carlson RW, Anderson BO, Chopra R, Eniu AE, Jakesz R, Love RR, Masetti R, Schwartsmann G. Breast J. 2003 May-Jun: 9 Suppl 2 S67-74
• Goals and objectives in the management of metastatic breast cancer. Chung CT, Carlson RW. Oncologist. 2003; 8 (6): 514-20
• NCCN breast cancer clinical practice guidelines in oncology: an update. Carlson RW, J Natl Compr Canc Netw. 2003: 1 Suppl 1 S61-3
• Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer. Hartman AR, Grekowicz A, Lum BL, Carlson RW, Schurman C, Sikic BI, Shapiro R, Stockdale FE. Breast Cancer Res Treat. 2003; 82 (1): 61-9
• Predictors of reexcision findings and recurrence after breast conservation. Smitt MC, Nowels K, Carlson RW, Jeffrey SS. Int J Radiat Oncol Biol Phys. 2003; 57 (4): 979-85
• Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Carlson RW, Henderson IC. Breast Cancer Res Treat. 2003: 80 Suppl 1 S19-26; discussion S27-8
• The role of aromatase inhibitors in early breast cancer. Chung CT, Carlson RW. Curr Treat Options Oncol. 2003; 4 (2): 133-40
• Sequencing of endocrine therapies in breast cancer--integration of recent data. Carlson RW, Breast Cancer Res Treat. 2002: 75 Suppl 1 S27-32; discussion S33-5
• NCCN: Breast cancer. Carlson RW, Edge SB, Theriault RL. Cancer Control. 2001 Nov-Dec; 8 (6 Suppl 2): 54-61
• Locally advanced breast cancer: is surgery necessary? Favret AM, Carlson RW, Goffinet DR, Jeffrey SS, Dirbas FM, Stockdale FE. Breast J. 2001 Mar-Apr; 7 (2): 131-7
• Supportive-expressive group therapy and distress in patients with metastatic breast cancer: a randomized clinical intervention trial. Classen C, Butler LD, Koopman C, Miller E, DiMiceli S, Giese-Davis J, Fobair P, Carlson RW, Kraemer HC, Spiegel D. Arch Gen Psychiatry. 2001; 58 (5): 494-501
• Management of breast cancer after Hodgkin's disease. Wolden SL, Hancock SL, Carlson RW, Goffinet DR, Jeffrey SS, Hoppe RT. J Clin Oncol. 2000; 18 (4): 765-72
• NCCN Practice Guidelines for Breast Cancer. Carlson RW, Anderson BO, Bensinger W, Cox CE, Davidson NE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Nabell LM, Reed EC, Silver SM, Smith ML, Somlo G, Theriault R, Ward JH, Winer EP, Wolff A. Oncology (Williston Park). 2000; 14 (11A): 33-49
• New bilateral microcalcifications at mammography in a postlactational woman: case report. Stucker DT, Ikeda DM, Hartman AR, George TI, Nowels KW, Birdwell SL, Goffinet D, Carlson RW. Radiology. 2000; 217 (1): 247-50
• Multidisciplinary Management of Locally Advanced Breast Cancer. Carlson RW, Favret AM. Breast J. 1999; 5 (5): 303-307
• Quality of life issues in the treatment of metastatic breast cancer. Carlson RW, Oncology (Williston Park). 1998; 12 (3 Suppl 4): 27-31
• Effects of medical and psychotherapeutic treatment on the survival of women with metastatic breast carcinoma. Kogon MM, Biswas A, Pearl D, Carlson RW, Spiegel D. Cancer. 1997; 80 (2): 225-30
• Scientific review of tamoxifen. Overview from a medical oncologist. Carlson RW, Semin Oncol. 1997; 24 (1 Suppl 1): S1-151-S1-7
• NCCN Breast Cancer Practice Guidelines. The National Comprehensive Cancer Network. Carlson RW, Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Moe RE, Theriault RL. Oncology (Williston Park). 1996; 10 (11 Suppl): 47-75
• Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer Piedbois P, Buyse M, Kemeny N, Rougier P, Carlson R, Allen-Mersh T, O'Connel M, Change A, Sondak V, Kemeny M, Levy. Journal of the National Cancer Institute. 1996: 88 252-258
• Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast. Hillner BE, Desch CE, Carlson RW, Smith TJ, Esserman L, Bear HD. J Clin Oncol. 1996; 14 (1): 70-7
• Computer-based screening of patients with HIV/AIDS for clinical-trial eligibility. Carlson RW, Tu SW, Lane NM, Lai TL, Kemper CA, Musen MA, Shortliffe EH. Online J Curr Clin Trials. 1995: Doc No 179 [3347 words; 32 paragraphs]
• The importance of the lumpectomy surgical margin status in long-term results of breast conservation. Smitt MC, Nowels KW, Zdeblick MJ, Jeffrey S, Carlson RW, Stockdale FE, Goffinet DR. Cancer. 1995; 76 (2): 259-67
• Integration of pen-based computer technology in clinical settings. Acuff RD, Fagan LM, Rindfleisch TC, Carlson RW, Tuttle MS, Sherertz DD. Proc Annu Symp Comput Appl Med Care. 1994: 1042
• Toward a patient-centered knowledge-server standard for CPRs. Tuttle MS, Sheretz DD, Fagan LM, Carlson RW, Cole WG, Schipma PB, Nelson SJ.. Proceedings of the 1994 Annual Healthcare Information and Management Systems Society Conference. 1994: 88 114-128
• A methodology for determining patients' eligibility for clinical trials. Tu SW, Kemper CA, Lane NM, Carlson RW, Musen MA. Methods Inf Med. 1993; 32 (4): 317-25
• Impact of omeprazole on the plasma clearance of methotrexate. Reid T, Yuen A, Catolico M, Carlson RW. Cancer Chemother Pharmacol. 1993; 33 (1): 82-4
• Reducing the cardiotoxicity of the anthracyclines. Carlson RW, Oncology (Williston Park). 1992; 6 (6): 95-100, 104, 107, discussion 107-8
• T-HELPER: automated support for community-based clinical research. Musen MA, Carlson RW, Fagan LM, Deresinski SC, Shortliffe EH. Proc Annu Symp Comput Appl Med Care. 1992: 719-23
• Late consolidative radiation therapy in the treatment of limited-stage small cell lung cancer. Carlson RW, Sikic BI, Gandara DR, Hendrickson CG, Wittlinger PS, Shields JA, Wong PP, White JE, Meakin CJ, McWhirter KM. Cancer. 1991; 68 (5): 948-58
• A multiinstitutional evaluation of the analgesic efficacy and safety of ketorolac tromethamine, acetaminophen plus codeine, and placebo in cancer pain. Carlson RW, Borrison RA, Sher HB, Eisenberg PD, Mowry PA, Wolin EM. Pharmacotherapy. 1990; 10 (3): 211-6
• A phase II trial of carbetimer for the treatment of colorectal cancer. A trial of the Northern California Oncology Group. Audeh MW, Jacobs CD, Davis TE, Carlson RW. Am J Clin Oncol. 1990; 13 (4): 324-6
• Successful treatment of metastatic thymic carcinoma with cisplatin, vinblastine, bleomycin, and etoposide chemotherapy. Carlson RW, Dorfman RF, Sikic BI. Cancer. 1990; 66 (10): 2092-4
• Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group. Carlson RW, Doroshow JH, Odujinrin OO, Flam MS, Malec M, Lamborn KR. Invest New Drugs. 1990; 8 (4): 387-9
• Enhancement of the clinical activity of melphalan by the hypoxic cell sensitizer misonidazole. Coleman CN, Carlson RW, Artim RA, Sampson WI, Lawrence HJ, Wong P, Halsey J, Kohler M, Gribble M, Sikic BI. Cancer Res. 1988; 48 (12): 3528-32
• The clinical biology of breast cancer. Carlson RW, Stockdale FE. Annu Rev Med. 1988: 39 453-64
• Combined modality therapy of locally advanced breast cancer. One institution's experience and a review of the literature. Hu E, Stockdale FE, Turner B, Carlson RW, Levine J, Kushlan P. Anticancer Res. 1987 Jul-Aug; 7 (4B): 733-6
• Phase II evaluation of oral medroxyprogesterone acetate in advanced breast cancer: a Northern California Oncology Group Study. Tan YO, Hendrickson C, McWhirter K, Kohler M, Hannigan JF, Carlson RW. Cancer Treat Rep. 1987; 71 (10): 969-70